AusperBio funding, valuation and investors

Overview

AusperBio is the operating name for AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., a biopharmaceutical company developing targeted oligonucleotide therapeutics for chronic hepatitis B (CHB) and other diseases. On August 27, 2026 the company announced a $120 million Series C led by a leading strategic investor that it did not name, with new participation from RA Capital Management and returning checks from HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. The company says the close brings capital raised since 2024 to $360 million. Lead candidate AHB-137 is an unconjugated antisense oligonucleotide designed to suppress HBsAg, inhibit viral DNA replication, and promote immune reactivation; it is in a Phase 3 trial in China after a global Phase 1 and multiple Phase 2 studies. AHB-171 is an investigational hepatocyte-targeted siRNA using the company’s Au-HALO delivery platform. Neither candidate has been approved by any regulator. Valuation and revenue were not disclosed. None of the named investors have Venture Capital Tracker /fund/ pages.

Why AusperBio is interesting

August 27, 2026: $120M Series C announced, bringing company-disclosed capital since 2024 to $360M. The lead is an unnamed strategic investor. RA Capital joined. Valuation was not disclosed. AHB-137 is in a Phase 3 trial in China and remains investigational.

Product & use cases

Two clinical oligonucleotide programs for chronic hepatitis B: an unconjugated ASO (AHB-137) and a liver-targeted siRNA (AHB-171), plus the Med-Oligo ASO and Au-HALO delivery platforms behind them.

• Chronic hepatitis B patients in the AHB-137 Phase 3 program in China
• Combination regimens that pair an ASO backbone with a targeted siRNA
• Later expansion of the same oligonucleotide platforms beyond HBV (company intention, not an approved franchise)

Key facts

• Aug 27, 2026: $120M Series C; unnamed strategic lead; RA Capital new (PR Newswire)
• Company: $360M raised since 2024 — cumulative, not this round alone
• AHB-137 in Phase 3 in China; investigational, not approved
• AHB-171 is the first clinical Au-HALO siRNA candidate (company)
• No valuation. No /fund/ pages for RA Capital, Qiming, Sherpa, CDH

Funding history (newest first)

Competitive landscape

Edge: A disclosed Phase 3 registrational program plus a second, delivery-platform siRNA — priced as $120 million of new equity with no mark. That is a clinical-stage capital signal, not a commercial product.

AusperBio is a Series C bet that an ASO backbone plus a targeted siRNA can move chronic HBV from chronic suppression to functional cure. Diligence is Phase 3 data and a named lead — not the WHO burden slide. Anagram prices a different clinical asset. Aktis shows RA Capital will also back public radiopharma.

• Anagram Therapeutics adjacent

  Another 2026 nine-figure private therapeutics print ($250M Blackstone, May). Different indication (EPI enzymes). See /startup/anagram-therapeutics.

• Aktis Oncology adjacent

  RA Capital led Aktis’s 2024 $175M Series B; Aktis is now public (AKTS). Radiopharma, not HBV. See /startup/aktis-oncology.

• Standard-of-care nucleos(t)ide analogues incumbent

  Company: current therapies can suppress replication but rarely achieve functional cure. That is AusperBio’s stated gap, not an efficacy claim for AHB-137.

Notable stories

• The August 27, 2026 release names RA Capital as new and leaves the lead as “a leading strategic investor.” Do not invent the lead.

Industries

Related funding articles

Venture Capital Tracker pieces that cover AusperBio's financing or category context.

• How Much Did AusperBio Raise? $120M Series C, No Valuation
• August 29–30 VC News: AusperBio $120M, Undisclosed Robotics and Docs, YC Winter 2027
• August 2026 VC News: What Closed Through the 30th?